Tenderwize
Wróć do wyszukiwania

Conclusion of non-exclusive drug discount agreement per §130a(8) SGB V via Open-House model for active substance lanthanum carbonate, chewable tablets

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Jul 31, 2028 · 704 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Lanthan(III)carbonat in der Darreichungsform Kautabletten

25/100

Ocena szansy

Needs reviewLow complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

25 / 100

Złożoność

20 / 100

Czynniki ryzyka

No guaranteed minimum purchase quantities; volumes depend on prescribing and dispensing patterns. The buyer explicitly...

The buyer reserves the right to terminate the Open-House procedure early if exclusive discount agreements are signed. T...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jul 2028
  • Conclusion of non-exclusive drug discount agreements for lanthanum carbonate chewable tablets.
  • No exclusivity; multiple pharmaceutical entrepreneurs can be contracted simultaneously.
Pokaż pełne podsumowanie

This is an Open-House model for concluding non-exclusive discount agreements under §130a Abs. 8 SGB V for the active substance lanthanum carbonate in chewable tablet form (ATC V03AE03). The procedure is open to all pharmaceutical entrepreneurs meeting the requirements, with no exclusivity or guaranteed purchase volumes. The agreement runs until 31 July 2028. The notice explicitly states it is not a public procurement under Directive 2014/24/EU but is published for transparency; the 'open procedure' designation is for technical reasons only.

Ryzyka

No guaranteed minimum purchase quantities; volumes depend on prescribing and dispensing patterns. The buyer explicitly...

The buyer reserves the right to terminate the Open-House procedure early if exclusive discount agreements are signed. T...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4 Abs. 18 AMG with respect to the offered drugs.

Eligibility

  • Must submit declaration of no exclusion grounds per §§123, 124 GWB.

Administrative

  • Must submit declaration regarding Russia sanctions per EU Regulation 833/2014.

Wymagania mogą być niepełne.

Kryteria udzielenia

Lot 1

No award criteria specified as this is an Open-House model without competition.

Zamawiający

Lokalizacja

Erfurt, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE256878834

Działalność

Health

Części (1)

LOT-0001

Conclusion of non-exclusive drug discount agreement per §130a(8) SGB V via Open-House model for active substance lanthanum carbonate, chewable tablets

Single lot covering the Open-House model for lanthanum carbonate chewable tablets. No estimated value, no minimum quantities. The agreement is non-exclusive and available to all qualified pharmaceutical entrepreneurs.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

Dresden, Germany

Czas trwania

Jul 2026 - Jul 2028

Kategoria

Pharmaceutical products

Kryteria udzielenia

No award criteria specified as this is an Open-House model without competition.

Termin

Expired Jul 07, 2026

Szczegóły zamówienia

Data publikacji
19 May 2026
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
344198-2026

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3